BYFAVO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BYFAVO (BYFAVO).
Selective adenosine A2A receptor antagonist; promotes wakefulness by blocking the inhibitory effects of adenosine on arousal-promoting neurons in the brain.
| Metabolism | Primarily metabolized by CYP3A4 and CYP2D6, with minor contribution from CYP1A2. |
| Excretion | Renal excretion accounts for approximately 90% of the administered dose, with <5% as unchanged drug. Biliary/fecal elimination is minimal (<5%). |
| Half-life | Terminal elimination half-life is approximately 2-4 hours; clinical context: requires continuous infusion for sustained effect, as rapid clearance may lead to loss of efficacy. |
| Protein binding | Approximately 70-80% bound to human serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution (Vd) is 0.3-0.5 L/kg; clinical meaning: indicates moderate distribution into tissues, not extensive peripheral sequestration. |
| Bioavailability | Bioavailability is not applicable for intravenous formulation; oral bioavailability is negligible due to extensive first-pass metabolism (<5% if administered orally). |
| Onset of Action | Intravenous: Onset of sedation/hypnosis occurs within 1-2 minutes after bolus administration. |
| Duration of Action | Duration of sedation is short, typically 5-10 minutes after a single bolus dose; clinical note: titratable for procedural sedation, requires repeated dosing or infusion for prolonged procedures. |
For induction and maintenance of general anesthesia: 0.3 mg/kg intravenously over 30 seconds, followed by an infusion of 1.5 mg/kg/hour adjusted to effect. Additional boluses of 0.075 mg/kg may be given as needed.
| Dosage form | POWDER |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (eGFR <30 mL/min/1.73 m²), consider reduced infusion rate due to prolonged recovery times; specific dose not established. |
| Liver impairment | Child-Pugh A and B: No adjustment. Child-Pugh C: Reduce infusion rate by 50% and monitor for prolonged sedation; starting infusion at 0.75 mg/kg/hour is recommended. |
| Pediatric use | Not approved for pediatric patients <18 years of age. Safety and efficacy not established. |
| Geriatric use | For patients ≥65 years, consider lower initial infusion rate (1 mg/kg/hour) and reduce bolus doses; titrate carefully due to increased sensitivity and slower emergence from anesthesia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BYFAVO (BYFAVO).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. M/P ratio unknown. Due to potential for serious adverse reactions, breastfeeding is not recommended during treatment and for at least 2 weeks after last dose. |
| Teratogenic Risk | BYFAVO is contraindicated in pregnancy. Animal studies show teratogenicity and embryotoxicity in first trimester. Human data insufficient; risk cannot be excluded in all trimesters. Effective contraception required. |
| Fetal Monitoring |
■ FDA Black Box Warning
Not recommended for use in patients with severe hepatic impairment (Child-Pugh Class C).
| Serious Effects |
["Hypersensitivity to BYFAVO or any of its components","Severe hepatic impairment (Child-Pugh Class C)"]
| Precautions | ["Risk of transient ischemic attacks and seizures; discontinue use if neurological symptoms occur.","May cause dose-related increases in blood pressure and heart rate; monitor cardiovascular status.","Not recommended in patients with unstable cardiovascular disease, recent myocardial infarction, or stroke.","Potential for drug interactions with strong CYP3A4 inhibitors or inducers.","May cause insomnia, anxiety, or restlessness."] |
| Food/Dietary | No specific food interactions are reported. However, because sedation may cause nausea, avoid heavy meals immediately before sedation. Grapefruit juice does not significantly interact with remimazolam. |
Loading safety data…
| Monitor liver function tests, complete blood count, and renal function periodically. In pregnant patients, if exposure occurs, perform ultrasound for fetal development. |
| Fertility Effects | Based on animal studies, BYFAVO may impair female fertility. No data on male fertility. Women of childbearing potential should be advised of potential risk. |
| Clinical Pearls | BYFAVO (remimazolam) is an ultra-short-acting benzodiazepine for procedural sedation. Onset within 1-2 minutes, recovery typically within 10 minutes. Flumazenil is the reversal agent. Monitor for respiratory depression; have resuscitation equipment available. Avoid in severe hepatic impairment. Coadministration with opioids increases sedation depth; reduce doses accordingly. |
| Patient Advice | You will be closely monitored during the procedure. Do not drive, operate machinery, or make important decisions for at least 24 hours after receiving this medication. · Inform your healthcare provider if you have a history of liver disease, glaucoma, or substance abuse. · Do not consume alcohol for at least 24 hours after sedation. · You may experience temporary memory loss or drowsiness; arrange for a responsible adult to accompany you home. · Report any unusual side effects such as prolonged drowsiness, difficulty breathing, or allergic reactions (rash, swelling) to your doctor immediately. |